In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead pays $400mm up front, plus earn-outs, to buy Nimbus Apollo and its ACC program for NASH

Executive Summary

Gilead Sciences Inc. paid $400mm up front to buy Nimbus Apollo Inc., a division of Nimbus Therapeutics. Gilead is particularly interested in Nimbus' Acteyl-CoA Carboxylase (ACC) inhibitor program for nonalcoholic steatohepatitis (NASH).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies